

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARTON BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Alpramil 12 mg/30 mg film-coated tablets  
milbemycin oxime/praziquantel

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:

**Active substances:**

Milbemycin oxime	12.0 mg
Praziquantel	30.0 mg

**3. PHARMACEUTICAL FORM**

Film-coated tablet

**4. PACKAGE SIZE**

1 tablet  
2 tablets  
4 tablets  
10 tablets  
20 tablets  
25 tablets  
40 tablets  
50 tablets  
100 tablets

**5. TARGET SPECIES**

Cats weighing at least 3 kg

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**MARKETING AUTHORISATION HOLDER**

Alfasan Nederland B.V.

Kuipersweg 9

3449 JA Woerden

The Netherlands

**DISTRIBUTED IN THE UK BY**

DUGV (UK) Ltd. Union House,

111 New Union Street,

Coventry, CV1 2NT

[uksales@dugganvet.com](mailto:uksales@dugganvet.com)

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 36408/5002

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**PVC / PE / PVDC / Aluminium blisters**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Alpramil 12 mg/30 mg film-coated tablets  
milbemycin oxime/praziquantel



**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Alfasan Nederland B.V.

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Lot {number}

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET:

**Alpramil 4 mg/10 mg film-coated tablets for cats weighing at least 0.5 kg**  
**Alpramil 12 mg/30 mg film-coated tablets for cats weighing at least 3 kg**  
**Alpramil 16 mg/40 mg film-coated tablets for cats weighing at least 4 kg**

### **1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Alfasan Nederland B.V.  
Kuipersweg 9  
3449 JA Woerden  
The Netherlands

Manufacturer responsible for batch release:

LelyPharma B.V.  
Zuiveringsweg 42  
8243 PZ Lelystad  
The Netherlands

### **2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Alpramil 4 mg/10 mg film-coated tablets for cats weighing at least 0.5 kg  
Alpramil 12 mg/30 mg film-coated tablets for cats weighing at least 3 kg  
Alpramil 16 mg/40 mg film-coated tablets for cats weighing at least 4 kg  
milbemycin oxime/praziquantel

### **3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each 4 mg/10 mg tablet contains:

#### **Active substances:**

Milbemycin oxime	4.0 mg
Praziquantel	10.0 mg

#### **Excipients:**

Titanium dioxide (E171)	0.186 mg
Quinoline Yellow (E104)	0.023 mg
Sunset Yellow FCF (E110)	0.004 mg

Film-coated tablet

Round and convex yellow coated tablet with a break line on one side.

Tablets can be divided into halves.

Each 12 mg/30 mg tablet contains:

**Active substances:**

Milbemycin oxime	12.0 mg
Praziquantel	30.0 mg

**Excipients:**

Titanium dioxide (E171)	0.456 mg
Iron oxide (E172)	0.181 mg

Film-coated tablet

Oblong and convex orange coated tablet.

Each 16 mg/40 mg tablet contains:

**Active substances:**

Milbemycin oxime	16.0 mg
Praziquantel	40.0 mg

**Excipients:**

Titanium dioxide (E171)	0.711 mg
Iron oxide (E172)	0.139 mg

Film-coated tablet

Oblong and convex purple-brown coated tablet.

#### **4. INDICATION(S)**

Treatment of mixed infections by immature and adult cestodes **and** nematodes of the following species:

- Cestodes:

*Dipylidium caninum*

*Taenia* spp.

*Echinococcus multilocularis*

- Nematodes:

*Ancylostoma tubaeforme*

*Toxocara cati*

Prevention of heartworm disease (*Dirofilaria immitis*) if concomitant treatment against cestodes is indicated.

#### **5. CONTRAINDICATIONS**

4 mg/10 mg tablet: Do not use in cats of less than 6 weeks of age and/or weighing less than 0.5 kg.

12 mg/30 mg tablet: Do not use in cats weighing less than 3 kg.

16 mg/40 mg tablet: Do not use in cats weighing less than 4 kg.

Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.



## 6. ADVERSE REACTIONS

On very rare occasions, especially in young cats, hypersensitivity reactions, systemic signs (such as lethargy), neurological signs (such as ataxia and muscle tremors) and/or gastrointestinal signs (such as emesis and diarrhoea) have been observed after administration of the veterinary medicinal product.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. Alternatively you can report via your national reporting system {national system details}.

## 7. TARGET SPECIES

4 mg/10 mg tablet: Cats weighing at least 0.5 kg

12 mg/30 mg tablet: Cats weighing at least 3 kg

16 mg/40 mg tablet: Cats weighing at least 4 kg





## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Oral use.



Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given orally as a single dose.

Animals should be weighed to ensure accurate dosing. Depending on the bodyweight of the cat and the availability of tablet sizes, practical dosing examples are as follows:



4 mg/10 mg tablet:

Weight (kg)	4 mg/10 mg tablet	
0.5 – 1		½ tablet
> 1 – 2		1 tablet
> 2 – 3		1½ tablets
> 3 – 4		2 tablets

12 mg/30 mg tablet:

Weight (kg)	12 mg/30 mg tablet	
> 3 – 6		1 tablet
> 6 – 12		2 tablets

16 mg/40 mg tablet:

Weight (kg)	16 mg/40 mg tablet	
> 4 – 8		1 tablet
> 8 – 16		2 tablets

## 9. ADVICE ON CORRECT ADMINISTRATION

The product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.

The product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The product has a duration of heartworm prevention of one month. For regular prevention of heartworm disease the use of a monosubstance is preferred.

## 10. WITHDRAWAL PERIOD(S)

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

4 mg/10 mg tablet: Shelf life of divided tablets after first opening the immediate packaging: 7 days

## 12. SPECIAL WARNING(S)

Special warnings for each target species:

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the cat should be taken into account, and it is recommended to seek professional advice.

It is recommended to treat all the animals living in the same household concomitantly.

When infection with the cestode *D. caninum* has been confirmed, concomitant treatment against intermediate hosts, such as fleas and lice, should be discussed with a veterinarian to prevent re-infection.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. Unnecessary use of

antiparasitics or use deviating from the instructions may increase the resistance selection pressure and lead to reduced efficacy.

Special precautions for use in animals:

No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may be harmful when ingested, particularly for children.

Avoid accidental ingestion.

Any unused tablet parts of 4 mg/10 mg tablets should be discarded or returned to the open blister, inserted back into the outer packaging and used at the next administration. The product should be stored in a safe place.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Other precautions:

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up and on the safeguard of persons need to be obtained from the relevant competent authority.

Pregnancy and lactation:

The product can be used in breeding cats including pregnant and lactating queens.

Interaction with other medicinal products and other forms of interaction:

The concurrent use of the product with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the product at the recommended dose.

Although not recommended, the concomitant use of the product with a spot on containing moxidectin and imidacloprid at recommended dose rates following a single application was well tolerated in one laboratory study in 10 kittens.

The safety and efficacy of the concurrent use have not been investigated in field studies. In the absence of further studies, caution should be taken in the case of concurrent use of the product with any other macrocyclic lactone. Also, no such studies have been performed with reproducing animals.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose, in addition to signs observed at the recommended dose (see Adverse Reactions), drooling was observed. This sign will usually disappear spontaneously within a day.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. The product should not enter water courses as this may be dangerous for fish and other aquatic organisms. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

July 2023

**15. OTHER INFORMATION**

PVC/PE/PVDC - Aluminium blisters containing 1, 2 or 4 tablets.

Box with 1 blister containing 1 tablet.  
Box with 1 blister containing 2 tablets.  
Box with 1 blister containing 4 tablets.  
Box with 10 blisters each containing 1 tablet.  
Box with 10 blisters each containing 2 tablets.  
Box with 10 blisters each containing 4 tablets.  
Box with 25 blisters each containing 1 tablet.  
Box with 25 blisters each containing 2 tablets.  
Box with 25 blisters each containing 4 tablets.

Not all pack sizes may be marketed.

**DISTRIBUTED IN THE UK BY**

DUGV (UK) Ltd. Union House,  
111 New Union Street,  
Coventry, CV1 2NT  
[uksales@dugganvet.com](mailto:uksales@dugganvet.com)



Approved: 25 July 2023